



June 17, 2020

BSE Ltd., Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai 400 001 Scrip Code: 532504 National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai 400 051 Scrip Code: NAVINFLUOR EQ

Dear Sirs,

Sub.: Investor Presentation – Q4FY20

Please find attached Investor Presentation for Q4FY20.

Kindly take the same on your records.

Thanking you,

Yours faithfully, For Navin Fluorine International Limited,

NIRAJ MANKAD Date: 2020.06.17 00:57:31 +05'30'

Niraj B. Mankad President Legal & Company Secretary



Navin Fluorine International Limited

Investor Presentation – Q4FY20



Safe Harbor




This presentation and the accompanying slides (the "**Presentation**"), which have been prepared by Navin Fluorine International Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forwardlooking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.





Responsible Care

On Standalone basis



Responsible Care

Highlights

On Standalone basis

High Value Business - Commentary





Specialty Business Unit

Well balanced growth driven by Life Science, Crop Science and Industrial segments CRAMS Business Unit

Strong order book positions business well for future profitable growth





Key Highlights \$61.5 Mn **\$410 Mn** (Rs. 436 crs) (**Rs. 2,800 crs**) **Contract Signed** Capex required with Global Company **7 Years** Contract Period; Sales will be evenly staggered ROC & **Margins** Expected Company level Commencement of EBIDTA & ROC for Supplies this project

Testament to our deep fluorine experience and success in scaling up of complex chemistries

- Entered into a \$410 million contract with a Global Company for manufacture and supply of a High-performance Product (HPP) in the fluorochemical space
- Project will be executed through wholly owned subsidiary Navin Fluorine Advanced Science
 Limited (NFASL) at Dahej in the state of Gujarat
- Investing \$51.5mn (Rs. 365 crs) for dedicated manufacturing facility and ~\$10mn (Rs.71 crs) for captive power plant
- The product is not part of the Navin Fluorine's existing product portfolio and is a new set of opportunities for application of fluorine for completely new segment
- Will manufacture both intermediate & final product
- Intermediate can be used for multi-product manufacturing, currently the contract is for one product

High performance product in fluorochemical space	Capex to be funded through internal accruals & debt	Royalty free access to technology	Through wholly owned subsidiary (NFASL)
--	--	---	--



COVID-19 Business Update





	•	 Taking necessary pr 	reventive measures like	workplace sanitization	, zoning, compu	lsory usage of masks etc.
--	---	---	-------------------------	------------------------	-----------------	---------------------------

- Daily thermal screening of employees at our factories
 - Implemented work from home policy for employees working at the corporate and branch offices

CSR Initiatives With a view to assist the Central/State Governments in their mammoth task of fighting with the COVID-19 pandemic, in the month of April, the Company made an aggregate contribution of Rs. 5,00,00,000/- to PM CARES FUND and the Chief Minister's Relief Funds of Maharashtra, Gujarat and Madhya Pradesh and continues to support various measures been taken by agencies in mitigating the impact of COVID-19

Strong Balance Sheet positions company well for long term profitable growth



Employees

Safety measure implemented to fight against Covid-19





Sanitization at entry point



Maintaining social distancing while traveling



Employee maintaining social distance at canteen area



Daily thermal screening of employees



Social distancing Morning briefing




Fully serviced Ambulance



Q4FY20: Robust Business Performance






Strong pipeline in Speciality and CRAMS to continue to drive growth momentum



9

FY20: Strong Performance continues






Sustainable and balanced growth to remain focus



Increasing Share of High Value Business





Growth momentum continues

- Strong Performance in domestic & export markets driven by higher volumes
- Product portfolio expansion and deeper penetration into existing users
- Strong project pipeline in Life Science & Crop Science continues to drive growth


Strong Orderbook Position


- Successful commissioning and operations of cGMP-3 plant
- Strong order book position as we moved into new financial year
- Strong enquiry flow from existing and new customers



Legacy Business Performance







Performance impacted by lower volumes

- Lower volumes in Q4 driven by soft demand in March due to lockdown
- Exports affected by quota issue faced by some of the buyers
- Non-emissive applications continue to show good growth

Performance Maintained

- Slower domestic demand compensated by good demand in international markets
- Domestic demand impacted due to slowdown in stainless steel industry
- Improved pricing in international markets helped maintain margins



Standalone Profitability Statement

13

X r	
181	MAFATLAL
4 X	GROUP

Particulars (Rs. Crs.)	Q4 FY20	Q4 FY19	Y-o-Y %	Q3 FY20	Q-o-Q %	FY20	FY19	Y-o-Y %
Net Revenue from Operations	265.0	244.3	8%	251.6	5%	1,022.3	955.1	7%
Raw Material	120.9	121.8		107.1		464.9	455.4	
Employee Expenses	30.0	23.2		29.3		111.8	96.9	
Other Expenses	47.0	47.0		50.0		184.8	184.7	
Operating EBITDA	67.2	52.2	29%	65.2	3%	260.7	218.1	20%
Operating EBITDA Margin	25.4%	21.4%	399 bps	25.9%	-54 bps	25.5%	22.8%	267 bps
Interest Expenses	0.5	0.2		0.4		1.6	0.5	
Depreciation	10.3	6.4		8.3		33.7	25.9	
Operating PBT	56.5	45.6	24%	56.5	-	225.4	191.8	18%
Operating PBT Margin	21.3%	18.7%	265 bps	22.4%	-113 bps	22.0%	20.1%	197 bps
Other Income	5.3	13.0		11.0		31.3	34.8	
РВТ	61.7	58.5		67.5		256.7	226.5	
Тах	-206.9*	22.6		22.2		-143.1*	78.0	
Profit After Tax	268.7	35.9		45.3		399.8	148.5	
Profit After Tax Margin	101.4%	14.7%		18.0%		39.1%	15.5%	
Other Comprehensive Income	-0.1	0.0		0.5		-0.7	-0.3	
Total Comprehensive income for the Period	268.6	36.0		45.8		399.1	148.2	

* The Company had contested receipts on account of Certified Emission Reduction (CER) as capital receipts not chargeable to tax from financial year 2007-08 to FY2012-13. During the year, it received favourable appellate orders for some of the aforesaid years. Accordingly, the Company has now recognized MAT Credit entitlement of Rs. 73.55 crs under section 115JAA of the Act, for which claims have been made. The Company has recomputed the tax liabilities for these years and written back excess tax provisions amounting to Rs. 141.25 crs for earlier years.



Standalone Balance Sheet




ASSETS (Rs. Crs.)	31-Mar-20	31-Mar-19	EQUITY AND LIABILITIES (Rs. Crs.)	31-Mar-20	31-Mar-19
Non-current assets	840.1	747.3			
Property, Plant and Equipment	359.1	279.6	EQUITY	1,388.9	1,059.2
Capital work-in-progress	38.9	39.3	Equity Share Capital	9.9	9.9
Right-of-use Assets	10.4	0.0	-		
Investment Property	42.4	43.2	Other Equity	1,379.1	1,049.3
Other Intangible Assets	1.0	1.3			
Investment in Subsidiaries, Associate & JV			Non-Current Liabilities	30.9	52.6
Venture	142.7	133.5			
Financial Assets			Provisions	10.3	8.6
(i) Investments	86.1	204.9	Deferred Tax Liabilities (Net)	-	29.5
(ii) Loans	15.1	16.0	Other non-current liabilities	13.5	14.5
(iil) Other Financial Assets	1.8	0.1			
Non-current tax assets	113.8	9.7	Other Financial Liabilities	7.1	0.0
Deferred tax assets (net)	19.4	-	Current liabilities	154.1	156.3
Other non-current assets	9.6	19.6			
			Financial Liabilities		
Current assets	733.9	520.8	(i) Borrowings		
Inventories	136.1	92.9	(ii) Trade Payables	92.2	67.9
Financial Assets					
(i) Investments	67.5	188.3	(iii) Other Financial Liabilities	31.8	23.4
(ii) Trade receivables	209.3	167.5	Contract Liabilities	2.1	3.5
(iii) Cash and cash equivalents	169.2	12.7	Drovisions	2.0	2.4
(iv) Bank balances other than (iii) above	94.9	9.7	Provisions	2.8	2.4
(v) Loans	6.7	7.2	Current Tax Liabilities (Net)	-	36.0
(vi) Others financial assets	5.9	2.0	Other Current Liabilities	25.2	23.2
Other Current Assets	44.3	40.6			
TOTAL ASSETS	1,574.0	1,268.1	TOTAL EQUITY AND LIABILITIES	1,574.0	1,268.1



Other Income Built-up








Other Income Built-up







Consolidated Profitability Statement

- <mark>K</mark> r		PADMANABH
		MAFATLAL
	ĕ	GROUP

Particulars (Rs. Crs.)	Q4 FY20	Q4 FY19	Y-o-Y %	Q3 FY20	Q-o-Q %	FY20	FY19	Y-o-Y %
Net Revenue from Operations	276.6	252.6	9%	260.5	6%	1,061.6	995.9	7%
Raw Material	125.7	127.3		111.2		483.8	476.6	
Employee Expenses	35.1	28.1		33.0		130.8	115.5	
Other Expenses	47.0	45.7		50.8		183.5	185.5	
Operating EBITDA	68.8	51.6	33%	65.5	5%	263.5	218.4	21%
Operating EBITDA Margin	24.9%	20.4%	444 bps	25.1%	-27 bps	24.8%	21.9%	290 bps
Interest Expenses	0.5	0.3		0.6		2.0	0.8	
Depreciation	11.1	6.7		9.2		37.0	27.5	
Operating PBT	57.2	44.6	28%	55.7	3%	224.5	190.0	18%
Operating PBT Margin	20.7%	17.6%	304 bps	21.4%	-70 bps	21.1%	19.1%	207 bps
Other Income	5.7	11.2		11.6		33.3	34.4	
РВТ	62.9	55.8	13%	67.3	-7%	257.8	224.4	15%
Тах	-207.2*	22.3		22.2		-143.6*	77.0	
Profit After Tax	270.1	33.5		45.1		401.4	147.4	
Profit After Tax Margin	97.7%	13.3%		17.3%		37.8%	14.8%	
Share of Profit from Associates and joint ventures (net)	2.6	1.7		0.3		7.2	1.7	
Profit for the period	272.7	35.2		45.4		408.6	149.1	
Other Comprehensive Income	0.1	0.4		2.7		0.5	-1.2	
Total Comprehensive income for the Period	272.8	35.5	30%	48.1		409.1	147.9	21%

* The Company had contested receipts on account of Certified Emission Reduction (CER) as capital receipts not chargeable to tax from financial year 2007-08 to FY2012-13. During the year, it received favourable appellate orders for some of the aforesaid years. Accordingly, the Company has now recognized MAT Credit entitlement of Rs. 73.55 crs under section 115JAA of the Act, for which claims have been made. The Company has recomputed the tax liabilities for these years and written back excess tax provisions amounting to Rs. 141.25 crs for earlier years.



17

Consolidated Balance Sheet

ASSETS (Rs. Crs.)

Goodwill

Venture

(ii) Loans

Financial Assets (i) Investments

Current assets Inventories Financial Assets (i) Investments (ii) Trade receivables

(v) Loans

TOTAL ASSETS

Non-current assets

Property, Plant and Equipment

Investment in Subsidiaries, Associate & JV

Capital work-in-progress Right-of-use Assets Investment Property Other Intangible Assets

(iil) Other Financial Assets Non-current tax assets Deferred tax assets (Net) Other non-current assets

(iii) Cash and cash equivalents

(vi) Others financial assets Other Current Assets

(iv) Bank balances other than (iii) above

31-Mar-20	31-Mar-19	EQUITY AND LIABILITIES (Rs. Crs.)	31-Mar-20	31-Mar-19
844.9	746.5			4 070 4
364.2	285.0	EQUITY	1,412.2	1,072.4
38.9	39.3	Equity Share Capital	9.9	9.9
20.8	0.0	Other Equity	1,402.3	1,062.6
55.0	56.2		1,402.5	1,002.0
1.0	1.3			
87.8	87.8	Non-Current Liabilities	39.1	57.9
40.5	33.3	Provisions	10.3	8.6
		Deferred Tax Liabilities (Net)	_	34.8
87.4	205.8			
7.5	7.3	Other non-current liabilities	13.5	14.5
2.3	0.1	Other Financial Liabilities	15.3	-
114.9	10.7	Current linkilities	177.0	170.0
15.1		Current liabilities	177.2	176.9
9.6	19.6	Financial Liabilities		
783.6	560.7	(i) Borrowings	1.4	4.1
157.9	111.9	(ii) Trade Payables	98.1	71.3
67.5	188.3	(iii) Other Financial Liabilities	35.5	25.0
218.5	172.7	Contract liabilities	2.1	3.5
176.7	15.9	Provisions	2.8	2.4
107.0	21.1			
4.5	4.8	Current Tax Liabilities (Net)	0.0	36.1
5.9	2.9	Other Current Liabilities	37.3	34.5
45.5	43.1	TOTAL EQUITY AND LIABILITIES	1,628.5	1,307.2
1,628.5	1,307.2		1,010.0	1,007.12



PADMANABH

MAFATLAL

Consolidated Cashflow Statement



Particulars (Rs in Crs)	31-Mar-20	31-Mar-19
Profit before tax	257.8	224.4
Adjustments for noncash items	15.7	-0.9
Operating profit before working capital changes	273.5	223.5
Working capital adjustments	-70.6	-61.5
Cash flows generated from operating activities	202.9	162.0
Income tax paid	-46.2	-71.9
Net Cash flows generated from operating activities (A)	156.6	90.2
Net Cash flows generated from investing activities (B)	85.1	-24.3
Net Cash flows generated from financing activities (C)	-80.9	-68.3
Net Cash Increase/(Decrease)	160.9	-2.5








Business Overview



Company Overview









CRAMS ✓ Business progression from Contract research to contract manufacturing ✓ Manufacturing facility commercially operational



Specialty Chemicals

- ✓ Introduction of new high value added molecules in portfolio
- ✓ Entry into newer geographies

Inorganic Fluorides


- ✓ Introduction of new molecules in portfolio
- \checkmark Entry into newer geographies

Refrigerant Gases

✓ Strong demand for air conditioning and refrigeration equipment ✓ Increasing usage as feedstock in pharma

... Growth driven by Every Business Unit








²³ * CRAMS business generating revenue since FY13 and Excludes Revenue from Dahej Operations of Rs. 55.68 Crs till 30th November 2017 for FY18


Key Strengths





Consistent Dividend Performance





Robust Dividend Payout

- ✓ Continuous Dividend over 10 years
- Special Dividend of 600% on FV of Rs. 10 in FY12
- Special Divided of 75% on FV of Rs. 10 in FY17
- ✓ Special of 150% on FV of Rs. 2 in FY18

The Company has recommended final dividend of Rs. 3 per share of FV of Rs. 2 each (150% of FV)





For further information, please contact:

Company :

Investor Relations Advisors :

Navin Fluorine International Ltd. CIN: L24110MH1998PLC115499 Strategic Growth Advisors Pvt. Ltd. CIN : U74140MH2010PTC204285

Mr. Ketan Sablok Chief Financial Officer <u>ketan.sablok@nfil.in</u>

<u>www.nfil.in</u>

Ms. Payal Dave / Ms. Neha Shroff 98199 16314 / 77380 73466 payal.dave@sgapl.net / neha.shroff@sgapl.net

www.sgapl.net

